NIP
LAB icon

Nicholas Investment Partners’s Standard BioTools LAB Stock Holding History

Nicholas Investment Partners’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-79,975
Closed -$3.06M – 312
2013
Q4 		$3.06M Buy
+79,975
New +$2.36M 0.23% 111

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nicholas Investment Partners's LAB Position: Q1 2014 in Review

Nicholas Investment Partners sold out of Standard BioTools (LAB) in Q1 2014, closing a stake of 79,975 shares — an estimated $3.06M sold.

Nicholas Investment Partners first reported a position in LAB in Q4 2013 and held it in 1 quarter. The position peaked at $3.06M in Q4 2013. 107 funds tracked by Wall St. Rank hold LAB as of Q1 2014.

  • Nicholas Investment Partners reported no remaining Standard BioTools position as of Q1 2014 after selling out during the quarter.
  • Nicholas Investment Partners sold 79,975 Standard BioTools shares in Q1 2014, an estimated $3.06M.
  • Nicholas Investment Partners first reported a position in Standard BioTools in Q4 2013 and held it in 1 quarter.
  • Nicholas Investment Partners's Standard BioTools position peaked at $3.06M in Q4 2013.
  • 107 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2014.

Based on Nicholas Investment Partners's 13F filing for Q1 2014, filed 8 May 2014.